NCT05921097

Brief Summary

Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe courses. Despite the frequent occurrence, the causes of diabetic peripheral neuropathy are largely unknown, which is reflected in the fact that no disease-modifying treatments are available for preventing, treating or even halting the progression of the disease. The consequences can be dire, as neuropathy frequently leads to foot ulcers, amputations or intolerable neuropathic pain in the lower extremities. Sensory loss may go completely undetected in diabetes, as there often are literally no symptoms. For many individuals, the development of diabetic peripheral neuropathy can therefore proceed completely unnoticed, making regular screening the most important tool for diagnosing the condition. Unfortunately, unlike nephropathy or retinopathy, diabetic peripheral neuropathy is not easily screened for, as the condition lacks reliable markers for early- or progressing disease. Therefore, screening for diabetic peripheral neuropathy currently revolves around diagnosing loss of protective sensation, judged by the inability to feel vibration or light touch. However, in their most recent guidelines, the American Diabetes Association has included screening for small fibre neuropathy using either the cold- and heat perception thresholds or pinprick as a clinical standard. Although this acknowledgement of the importance of assessing not only large- but also small nerve fibres is a huge step towards early detection of diabetic peripheral neuropathy, the overriding issue of insensitive, unreproducible, and inaccurate bedside tests for small nerve fibres remains. While cold- and heat perception and pinprick sensation are indeed mediated by small nerve fibres, the sensitivity of these methods, outside of extreme standardization only achievable in dedicated neuropathy research-centres, remain poor and not usable on an individual level. This lack of sensitivity has also become apparent in several large clinical trials, where the methods have continuously failed as robust clinical endpoints. Due to this, the hunt for a sensitive and reproducible method for adequate assessment of the small nerve fibres have begun. Amongst several interesting methods, two have gained particular interest (corneal confocal microscopy and skin biopsies with quantification of intra-epidermal nerve fiber density), due to their diverse strengths, although clinical application is currently limited to a few specialized sites. Furthermore, both methods suffer several inherent issues including that fact that they only provide information about the structure of the nerves and not the function. One method to assess the function of small cutaneous C-fibers is the assessment of the axon reflex flare response using laser doppler imaging (LDI) or Full-field laser perfusion imaging (FLPI), which has classically been studied using local heating. Unfortunately, this method is limited in clinical usage due to time-consumption. The investigators recently published an alternative method using a simple skin-prick application of histamine to evoke the response, which reduced the examination-time markedly. Before claiming the method to be a better alternative, the investigators do however need to prove that the method is as good as the original. In addition to the direct comparison of the histamine-induced and the heating-induced axon-reflex flare response the study will also assess spatial acuity in the same cohort as a secondary aim. Spatial acuity is considered as a measure of the sensory systems ability to code spatial information regarding an external stimulus. To investigate the spatial acuity, the 2-point discrimination task (2PDT) is often used. Spatial acuity has been shown to be impaired in several chronic pain condition. Additionally, it has been shown that the 2PDT may be a useful tool to understand the sensory changes in diabetes\[8\].

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2023

Completed
10 days until next milestone

Study Start

First participant enrolled

June 17, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 27, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 17, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 29, 2024

Completed
Last Updated

July 30, 2024

Status Verified

July 1, 2024

Enrollment Period

1 year

First QC Date

June 7, 2023

Last Update Submit

July 29, 2024

Conditions

Keywords

DiabetesNeuropahty

Outcome Measures

Primary Outcomes (2)

  • Comparison of histamine and local heating (area size)

    The evoked area (assessed by full-field laser speckle perfusion imaging) by histamine and local heating will be compared as a proxy for small fiber neuropathy in diabetes

    Through study completion, an average of 1-2 years

  • Comparison of axon-reflex flare responses with QST

    Comparison of axon reflex flare responses with an established method (area size vs cold and heat detection threshold)

    Through study completion, an average of 1-2 years

Secondary Outcomes (2)

  • 2PDT in diabetes with and without DPN

    Through study completion, an average of 1-2 years

  • Comparison of axon-reflex flare responses with NC-Stat DPNCheck

    Through study completion, an average of 1-2 years

Other Outcomes (2)

  • Exploratory

    Through study completion, an average of 1-2 years

  • DPN severity and pain

    Through study completion, an average of 1-2 years

Study Arms (1)

T1DM

People with type 1 diabetes

Diagnostic Test: Histamin-induced axon-reflex flare responseDiagnostic Test: Local heating-induced axon-reflex flare responseDiagnostic Test: 2-point discrimination tasksDiagnostic Test: NC-Stat DPNCheckDiagnostic Test: QSTDiagnostic Test: Biothesiometry

Interventions

Histamin-induced axon-reflex flare response

T1DM

Local heating-induced axon-reflex flare response

T1DM

2-point discrimination tasks

T1DM
NC-Stat DPNCheckDIAGNOSTIC_TEST

NC-Stat DPNCheck

T1DM
QSTDIAGNOSTIC_TEST

QST

Also known as: Quantitative Sensory Testing, thermal
T1DM
BiothesiometryDIAGNOSTIC_TEST

Biothesiometry

Also known as: VPT
T1DM

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

People with T1DM

You may qualify if:

  • Age 18-75 years and diagnosed with type 1 diabetes

You may not qualify if:

  • Known critical limb ischemia (ankle-brachial index \< 50 mmHg or toe-brachial index \< 30 mmHg)
  • Symptoms of claudicatio intermittens
  • Inability to do without antihistamine for 24h prior to examination
  • Known neurological disease (e.g., multiple sclerosis)
  • Severe skin diseases on either foot (e.g., fulminant pemphigoid)
  • Previous or current alcohol or drug abuse
  • Previous or current chemotherapy or current disseminated cancer
  • Known cause of neuropathy other than diabetes
  • Previous amputation on either foot
  • Active diabetic foot ulcer on either foot
  • Pregnancy
  • Inability to participate or other condition thought to impact the results (evaluated by investigator)
  • Asymmetrical neuropathy (i.e., previous accident with radiating pain)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg University Hospital

Aalborg, 9000, Denmark

Location

MeSH Terms

Conditions

Diabetes MellitusDiabetes Mellitus, Type 1Small Fiber Neuropathy

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Postdoc

Study Record Dates

First Submitted

June 7, 2023

First Posted

June 27, 2023

Study Start

June 17, 2023

Primary Completion

June 17, 2024

Study Completion

July 29, 2024

Last Updated

July 30, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Locations